亿帆医药(002019.SZ)：褪黑素颗粒药品注册获受理

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the registration and marketing authorization of melatonin granules from the National Medical Products Administration on August 5, 2025. The product is intended to improve sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1]. Group 1 - The melatonin granules are specifically designed for children aged 6-15 [1]. - The product addresses sleep difficulties associated with neurodevelopmental disorders [1].